GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » EV-to-EBITDA

Heidelberg Pharma AG (XTER:HPHA) EV-to-EBITDA : -6.20 (As of May. 25, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Heidelberg Pharma AG's enterprise value is €104.54 Mil. Heidelberg Pharma AG's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was €-16.87 Mil. Therefore, Heidelberg Pharma AG's EV-to-EBITDA for today is -6.20.

The historical rank and industry rank for Heidelberg Pharma AG's EV-to-EBITDA or its related term are showing as below:

XTER:HPHA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.12   Med: -5.4   Max: -1.3
Current: -6.2

During the past 13 years, the highest EV-to-EBITDA of Heidelberg Pharma AG was -1.30. The lowest was -15.12. And the median was -5.40.

XTER:HPHA's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs XTER:HPHA: -6.20

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Heidelberg Pharma AG's stock price is €2.94. Heidelberg Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was €-0.400. Therefore, Heidelberg Pharma AG's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Heidelberg Pharma AG EV-to-EBITDA Historical Data

The historical data trend for Heidelberg Pharma AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG EV-to-EBITDA Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.47 -8.89 -7.31 -12.42 -4.87

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.58 -5.29 -5.74 -4.87 -6.53

Competitive Comparison of Heidelberg Pharma AG's EV-to-EBITDA

For the Biotechnology subindustry, Heidelberg Pharma AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's EV-to-EBITDA falls into.



Heidelberg Pharma AG EV-to-EBITDA Calculation

Heidelberg Pharma AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=104.540/-16.873
=-6.20

Heidelberg Pharma AG's current Enterprise Value is €104.54 Mil.
Heidelberg Pharma AG's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG  (XTER:HPHA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Heidelberg Pharma AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.94/-0.400
=At Loss

Heidelberg Pharma AG's share price for today is €2.94.
Heidelberg Pharma AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.400.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Heidelberg Pharma AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines